The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 1, 2006, Pages 55-60

  Guldiken, Sibel ^a   Turgut, Burhan ^a   Demir, Muzaffer ^a,b,c   Arikan, Ender ^a   Kara, Mujdat ^a   Vural, Ozden ^a   Tugrul, Armagan ^a   Fareed, Jawed ^b  

^a TRAKYA UNIVERSITY   (Turkey)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Fibrinolytic system; Insulin resistance; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; TROGLITAZONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT COURSE THERAPY; WAIST CIRCUMFERENCE;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOLYSIS; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZOLIDINEDIONES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 32344447682     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960601200109     Document Type: Article

References (29)

1. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;2:3.
2. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457.
3. Kwaan HC. Changes in blood coagulation, platelet function and plasminogen-plasmin system in diabetes. Diabetes 1992;41(suppl 2):32.
4. Reaven GM. 1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595.
5. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988.
6. Kruithof EK, Tran-Thang C, Bachmann F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Hemost 1986;55:201.
7. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987;70:343.
8. Amiral J. The global fibrinolytic capacity. Fibrinolysis 1996;10:95.
9. Amiral J, Malmejac A, Gin H, et al. Evaluation of the fibrinolytic potential on plasma: Physiological and pathological variations, and associations with cardiovascular disease risk factors. Fibrin Proteol 1999;13:1.
10. Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999;57:921.
11. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 1997;26:553.
12. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280.
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412.
14. Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep 2004;4:63.
15. Juhan-Vague I, Vague P. Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease. Am J Obstet Gynecol 1990;163:313.
16. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:371.
17. Alessi MC, Juhan-Vague I, Kooistra T, et al. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Hemost 1988;60:491.
18. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994;89:321.
19. Vuorinen-Markkola H, Puhakainen I, Yki-Jarvinen H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Hemost 1992;67:117.
20. Grant PJ, Kruithof EK, Felley CP, et al. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 1990;79:513.
21. Calles-Escandon J, Mirza SA, Sobel BE, et al. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998;47:290.
22. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460.
23. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 1996;2:800.
24. Eriksson P, Reynisdottir S, Lonnqvist F, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998;41:65.
25. Yildiz BO, Haznedaroglu IC, Kirazli S, et al. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002;87:3871.
26. McTernan PG, Harte AL, Anderson LA, et al. Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes 2002;51:1493.
27. Mcternan PG, Eggo MC, Smith SA, et al. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in cultured human hepatocytes in human subcutaneous adipocytes. Diabetes 2001;50(suppl. 2):A275.
28. Fonseca VA, Reynolds T, Hemphill D, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998;12:181.
29. Goldstein BJ, Fuell D, Menci L, et al. Rosiglitazone in combination with glibenclamide: Effect on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetes Res Clin Pract 2000;50(suppl. 1):A64.